

Petra Baji

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8569655/publications.pdf>

Version: 2024-02-01

82
papers

1,717
citations

279798

23
h-index

330143

37
g-index

90
all docs

90
docs citations

90
times ranked

2229
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Alopecia areata and health-related quality of life: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2016, 175, 561-571. | 1.5 | 144 |
| 2 | Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 65-71. | 2.8 | 108 |
| 3 | EQ-5D in Central and Eastern Europe: 2000–2015. <i>Quality of Life Research</i> , 2016, 25, 2693-2710. | 3.1 | 103 |
| 4 | Biosimilars for the management of rheumatoid arthritis: economic considerations. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 43-52. | 3.0 | 83 |
| 5 | Health promotion targeting older people. <i>BMC Health Services Research</i> , 2016, 16, 345. | 2.2 | 66 |
| 6 | The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. <i>Advances in Therapy</i> , 2017, 34, 1128-1144. | 2.9 | 64 |
| 7 | Psychometric properties of the Hungarian version of the eHealth Literacy Scale. <i>European Journal of Health Economics</i> , 2019, 20, 57-69. | 2.8 | 49 |
| 8 | Informal payments for healthcare services and short-term effects of the introduction of visit fee on these payments in Hungary. <i>International Journal of Health Planning and Management</i> , 2012, 27, 63-79. | 1.7 | 48 |
| 9 | User fees for public health care services in Hungary: Expectations, experience, and acceptability from the perspectives of different stakeholders. <i>Health Policy</i> , 2011, 102, 255-262. | 3.0 | 44 |
| 10 | A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 1-7. | 1.4 | 44 |
| 11 | Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 89-98. | 2.8 | 41 |
| 12 | Changes in Equity in Out-of-pocket Payments during the Period of Health Care Reforms: Evidence from Hungary. <i>International Journal for Equity in Health</i> , 2012, 11, 36. | 3.5 | 36 |
| 13 | Access to biologics in Crohn's disease in ten European countries. <i>World Journal of Gastroenterology</i> , 2017, 23, 6294. | 3.3 | 35 |
| 14 | Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. <i>Current Medicinal Chemistry</i> , 2019, 26, 259-269. | 2.4 | 34 |
| 15 | Exploring consumers' attitudes towards informal patient payments using the combined method of cluster and multinomial regression analysis - the case of Hungary. <i>BMC Health Services Research</i> , 2013, 13, 62. | 2.2 | 33 |
| 16 | Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary. <i>PLoS ONE</i> , 2014, 9, e107704. | 2.5 | 31 |
| 17 | Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 99-108. | 2.8 | 31 |
| 18 | Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 22-27. | 1.5 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods. <i>Pain</i> , 2017, 158, 2259-2267. | 4.2 | 30 |
| 20 | Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. <i>European Journal of Health Economics</i> , 2014, 15, 45-52. | 2.8 | 27 |
| 21 | Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. <i>European Journal of Health Economics</i> , 2014, 15, 53-64. | 2.8 | 26 |
| 22 | Informal cash payments for birth in Hungary: Are women paying to secure a known provider, respect, or quality of care?. <i>Social Science and Medicine</i> , 2017, 189, 86-95. | 3.8 | 25 |
| 23 | Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2015, 173, 1076-1080. | 1.5 | 24 |
| 24 | Cost-of-illness studies in nine Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2019, 20, 155-172. | 2.8 | 23 |
| 25 | Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. <i>European Journal of Health Economics</i> , 2014, 15, 101-109. | 2.8 | 22 |
| 26 | Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 597-606. | 1.4 | 22 |
| 27 | The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys. <i>European Journal of Health Economics</i> , 2019, 20, 5-16. | 2.8 | 22 |
| 28 | Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 942-943. | 0.9 | 21 |
| 29 | Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. <i>United European Gastroenterology Journal</i> , 2018, 6, 310-321. | 3.8 | 20 |
| 30 | EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. <i>Kardiologia Polska</i> , 2018, 76, 860-870. | 0.6 | 19 |
| 31 | Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. <i>Pathology and Oncology Research</i> , 2015, 21, 619-627. | 1.9 | 17 |
| 32 | Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs. <i>BMC Geriatrics</i> , 2017, 17, 233. | 2.7 | 17 |
| 33 | Unmet medical needs in ambulatory care in Hungary: forgone visits and medications from a representative population survey. <i>European Journal of Health Economics</i> , 2019, 20, 71-78. | 2.8 | 17 |
| 34 | A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. <i>European Journal of Health Economics</i> , 2019, 20, 119-132. | 2.8 | 17 |
| 35 | Exploring eHealth Literacy and Patient-Reported Experiences With Outpatient Care in the Hungarian General Adult Population: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e19013. | 4.3 | 17 |
| 36 | Discrepancies between the Dermatology Life Quality Index and utility scores. <i>Quality of Life Research</i> , 2016, 25, 1687-1696. | 3.1 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. <i>British Journal of Dermatology</i> , 2016, 175, 593-599. | 1.5 | 15 |
| 38 | Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 139-147. | 1.9 | 15 |
| 39 | Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 27-34. | 2.8 | 14 |
| 40 | The link between past informal payments and willingness of the Hungarian population to pay formal fees for health care services: results from a contingent valuation study. <i>European Journal of Health Economics</i> , 2014, 15, 853-867. | 2.8 | 13 |
| 41 | Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data. <i>Quality of Life Research</i> , 2020, 29, 2863-2874. | 3.1 | 13 |
| 42 | Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective. <i>European Journal of Health Economics</i> , 2014, 15, 73-82. | 2.8 | 12 |
| 43 | Adaptation or recovery after health shocks? Evidence using subjective and objective health measures. <i>Health Economics (United Kingdom)</i> , 2018, 27, 850-864. | 1.7 | 12 |
| 44 | Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies. <i>European Journal of Health Economics</i> , 2019, 20, 141-154. | 2.8 | 12 |
| 45 | Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists. <i>Value in Health Regional Issues</i> , 2016, 10, 85-90. | 1.2 | 11 |
| 46 | Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary. <i>European Journal of Health Economics</i> , 2019, 20, 17-30. | 2.8 | 11 |
| 47 | Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries. <i>European Journal of Health Economics</i> , 2016, 17, 791-799. | 2.8 | 10 |
| 48 | Patient experiences with outpatient care in Hungary: results of an online population survey. <i>European Journal of Health Economics</i> , 2019, 20, 79-90. | 2.8 | 10 |
| 49 | Comparing cost-sharing practices for pharmaceuticals and health care services among four central European countries. <i>Society and Economy</i> , 2012, 34, 221-240. | 0.3 | 9 |
| 50 | EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. <i>Rheumatology International</i> , 2017, 37, 1957-1977. | 3.0 | 9 |
| 51 | Assessing quality of maternity care in Hungary: expert validation and testing of the mother-centered prenatal care (MCPC) survey instrument. <i>Reproductive Health</i> , 2017, 14, 152. | 3.1 | 9 |
| 52 | EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. <i>European Journal of Health Economics</i> , 2019, 20, 109-117. | 2.8 | 8 |
| 53 | Preferences of Hungarian consumers for quality, access and price attributes of health care services – result of a discrete choice experiment. <i>Society and Economy</i> , 2012, 34, 293-311. | 0.3 | 7 |
| 54 | Dermatology Life Quality Index (DLQI) score bands are applicable to DLQI-Relevant (DLQI-R) scoring. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e484-e486. | 2.4 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Examining obstetric interventions and respectful maternity care in Hungary: Do informal payments for continuity of care link to quality?. <i>Birth</i> , 2021, 48, 309-318. | 2.2 | 7 |
| 56 | Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving. <i>Pharmacoeconomics</i> , 2020, 38, 633-643. | 3.3 | 6 |
| 57 | Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. <i>Quality of Life Research</i> , 2021, 30, 629-641. | 3.1 | 6 |
| 58 | Development of Population Tariffs for the ICECAP-A Instrument for Hungary and their Comparison With the UK Tariffs. <i>Value in Health</i> , 2021, 24, 1845-1852. | 0.3 | 6 |
| 59 | Long-term costs and survival of prostate cancer: a population-based study. <i>International Urology and Nephrology</i> , 2017, 49, 1707-1714. | 1.4 | 5 |
| 60 | Does the Implementation of Official User Charges Help to Eradicate Informal Payments – Lessons to be Learnt from the Hungarian Experience. <i>Frontiers in Public Health</i> , 2015, 3, 181. | 2.7 | 4 |
| 61 | Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD). <i>Applied Research in Quality of Life</i> , 2017, 12, 409-424. | 2.4 | 4 |
| 62 | Eliciting preferences for outpatient care experiences in Hungary: A discrete choice experiment with a national representative sample. <i>PLoS ONE</i> , 2020, 15, e0235165. | 2.5 | 4 |
| 63 | Comparing the measurement properties of the ICECAP-A and ICECAP-O instruments in ages 50–70: a cross-sectional study on a representative sample of the Hungarian general population. <i>European Journal of Health Economics</i> , 2021, 22, 1453-1466. | 2.8 | 4 |
| 64 | Understanding the use of patient-reported data by health care insurers: A scoping review. <i>PLoS ONE</i> , 2020, 15, e0244546. | 2.5 | 4 |
| 65 | Comparing self-perceived and estimated fracture risk by FRAX® of women with osteoporosis. <i>Archives of Osteoporosis</i> , 2017, 12, 4. | 2.4 | 3 |
| 66 | Acceptable health and ageing: results of a cross-sectional study from Hungary. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 346. | 2.4 | 3 |
| 67 | Self-Reported Waiting Times for Outpatient Health Care Services in Hungary: Results of a Cross-Sectional Survey on a National Representative Sample. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2213. | 2.6 | 3 |
| 68 | PNS197 WAITING TIMES FOR HEALTH CARE SERVICES IN HUNGARY - RESULTS OF A REPRESENTATIVE POPULATION SURVEY. <i>Value in Health</i> , 2019, 22, S794. | 0.3 | 2 |
| 69 | Patient experiences in a public primary health care clinic: A South African case study. <i>Society and Economy</i> , 2020, 42, 333-347. | 0.3 | 2 |
| 70 | The impact of the recession on health care expenditure – How does the Czech Republic, Hungary, Poland and Slovakia compare to other OECD countries?. <i>Society and Economy</i> , 2015, 37, 73-88. | 0.3 | 1 |
| 71 | Musculoskeletal health and capability wellbeing: Associations between the HAQ-DI, ICECAP-A and ICECAP-O measures in a population survey. <i>Musculoskeletal Science and Practice</i> , 2021, 55, 102420. | 1.3 | 1 |
| 72 | Long-term care financing in Europe: An overview. <i>Zdrowie Publiczne I Zarządzanie</i> , 2019, 17, 131-145. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|----|-----------|
| 73 | Title is missing!. , 2020, 15, e0235165. | | 0 |
| 74 | Title is missing!. , 2020, 15, e0235165. | | 0 |
| 75 | Title is missing!. , 2020, 15, e0235165. | | 0 |
| 76 | Title is missing!. , 2020, 15, e0235165. | | 0 |
| 77 | Title is missing!. , 2020, 15, e0235165. | | 0 |
| 78 | Title is missing!. , 2020, 15, e0235165. | | 0 |
| 79 | Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546. | | 0 |
| 80 | Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546. | | 0 |
| 81 | Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546. | | 0 |
| 82 | Understanding the use of patient-reported data by health care insurers: A scoping review. , 2020, 15, e0244546. | | 0 |